Literature DB >> 6693176

Chemotactic and phagocytic responses of human alveolar macrophages to activated complement components.

S W Richards, P K Peterson, H A Verbrugh, R D Nelson, D E Hammerschmidt, J R Hoidal.   

Abstract

Human alveolar macrophages (AMs) migrated toward and aggregated to C5a but not toward C5a-deficient serum. Human AMs from cigarette smokers migrated significantly farther than did AMs from nonsmokers. Human AMs phagocytized Escherichia coli opsonized with activated C3. Immunoglobulin G was not required for phagocytosis. Human AMs demonstrate chemotaxis and aggregation to C5a. Further, human AMs can phagocytize bacteria coated with activated C3.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6693176      PMCID： PMC264372          DOI： 10.1128/iai.43.2.775-778.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  16 in total

1.  Complement (C3)-activated phagocytosis by lung macrophages.

Authors:  S B Shurin; T P Stossel
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

2.  Human polymorphonuclear leucocyte receptors for staphylococcal opsonins.

Authors:  J Verhoef; P K Peterson; P G Quie
Journal:  Immunology       Date:  1977-08       Impact factor: 7.397

3.  Bronchopulmonary lavage in normal subjects and patients with obstructive lung disease.

Authors:  T N Finley; E W Swenson; W S Curran; G L Huber; A J Ladman
Journal:  Ann Intern Med       Date:  1967-04       Impact factor: 25.391

4.  Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a.

Authors:  H N Fernandez; T E Hugli
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

5.  Receptors for immunoglobulin and complement on human alveolar macrophages.

Authors:  H Y Reynolds; J P Atkinson; H H Newball; M M Frank
Journal:  J Immunol       Date:  1975-06       Impact factor: 5.422

Review 6.  Phagocytosis. Clinical disorders of recognition and ingestion.

Authors:  T P Stossel
Journal:  Am J Pathol       Date:  1977-09       Impact factor: 4.307

Review 7.  Defense mechanisms of the respiratory membrane.

Authors:  G M Green; G J Jakab; R B Low; G S Davis
Journal:  Am Rev Respir Dis       Date:  1977-03

8.  Kinetics of phagocytosis and bacterial killing by human polymorphonuclear leukocytes and monocytes.

Authors:  P K Peterson; J Verhoef; D Schmeling; P G Quie
Journal:  J Infect Dis       Date:  1977-10       Impact factor: 5.226

9.  Quantification of mouse macrophage chemotaxis in vitro: role of C5 for the production of chemotactic activity.

Authors:  R Snyderman; M C Pike; D McCarley; L Lang
Journal:  Infect Immun       Date:  1975-03       Impact factor: 3.441

10.  Pulmonary alveolar macrophage. Defender against bacterial infection of the lung.

Authors:  E Goldstein; W Lippert; D Warshauer
Journal:  J Clin Invest       Date:  1974-09       Impact factor: 14.808
View more
  4 in total

1.  Interactions between alveolar macrophage subpopulations modulate their migratory function.

Authors:  C Laplante; I Lemaire
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

Review 2.  Immune and inflammatory function in cigarette smokers.

Authors:  P G Holt
Journal:  Thorax       Date:  1987-04       Impact factor: 9.139

3.  Antimicrobial activities of dialysate-elicited and resident human peritoneal macrophages.

Authors:  P K Peterson; E Gaziano; H J Suh; M Devalon; L Peterson; W F Keane
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

4.  Smoking decreases the response of human lung macrophages to double-stranded RNA by reducing TLR3 expression.

Authors:  Jill C Todt; Christine M Freeman; Jeanette P Brown; Joanne Sonstein; Theresa M Ames; Alexandra L McCubbrey; Fernando J Martinez; Stephen W Chensue; James M Beck; Jeffrey L Curtis
Journal:  Respir Res       Date:  2013-03-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.